Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFATC1 | O95644 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22276465 | 0.72 | DYRK1A (0.40) | NFATC1GSK3BDYRK1A | |
| SCHEMBL12874842 | 0.71 | DYRK1A (0.62) | NFATC1GSK3BDYRK1A | |
| SCHEMBL24117380 | 0.68 | PDPK1 (0.36) | NFATC1GSK3BDYRK1A | |
| SCHEMBL24117379 | 0.61 | NFATC1 (0.50) | NFATC1GSK3BDYRK1A | |
| SCHEMBL3218061 | 0.61 | DYRK1A (0.43) | NFATC1GSK3BDYRK1A | |
| SCHEMBL16019431 | 0.59 | DYRK1A (0.56) | NFATC1GSK3BDYRK1A | |
| SCHEMBL12889390 | 0.57 | DYRK1A (0.64) | NFATC1GSK3BDYRK1A | |
| SCHEMBL23034600 | 0.56 | TLR8 (0.36) | — | |
| SCHEMBL3218054 | 0.56 | DYRK1A (0.41) | NFATC1GSK3BDYRK1A | |
| SCHEMBL21917358 | 0.56 | DYRK1A (0.62) | NFATC1GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395221-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS INC (US) | 2021-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395221-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | NFATC1 1132/4885GSK3B 2904/4885DYRK1A 4407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.